Tiansu Wang
About Tiansu Wang
Tiansu Wang is a Scientist II specializing in Cell Therapy Discovery at ElevateBio, with a background in functional genomics and gene editing. He has held positions at notable institutions, including the Icahn School of Medicine at Mount Sinai and CRISPR Therapeutics, and has a PhD in Cellular and Molecular Biology from the National University of Singapore.
Current Role at ElevateBio
Tiansu Wang holds the position of Scientist II in Cell Therapy Discovery at ElevateBio. He has been with the company since 2022 and is based in Waltham, Massachusetts. In this role, he focuses on advancing cell therapy research and development, contributing his expertise in functional genomics and in vitro modeling.
Previous Experience at CRISPR Therapeutics
Prior to his current role, Tiansu Wang worked as a Scientist I at CRISPR Therapeutics from 2021 to 2022 in Cambridge, Massachusetts. His responsibilities included gene editing and induced pluripotent stem cell (iPSC) differentiation. This position allowed him to further develop his skills in gene editing technologies.
Postdoctoral Fellowship at Icahn School of Medicine
Tiansu Wang served as a Postdoctoral Fellow at the Icahn School of Medicine at Mount Sinai from 2016 to 2021 in New York, New York. During this five-year tenure, he engaged in advanced research projects, enhancing his expertise in cellular and molecular biology.
Educational Background
Tiansu Wang earned his Doctor of Philosophy (PhD) in Cell/Cellular and Molecular Biology from the National University of Singapore, where he studied from 2010 to 2015. He also obtained a Bachelor of Science (B.Sc.) in Biology/Biological Sciences from Sun Yat-Sen University, completing his degree from 2006 to 2010.
Research Skills and Expertise
Tiansu Wang possesses strong research skills in functional genomics techniques, including RNA-seq and ATAC-seq. He has demonstrated a history of in vitro modeling of leukemia using induced pluripotent stem cells (iPSCs) and has experience with flow cytometry, particularly in immune cell therapy research.